[1] SCARAMUZZO G, ORRAVIANI I, VOLTA CA, et al.Mechanical ventilation and COPD: from pathophysiology to ventilatory management[J]. Minerva Med, 2022,113(3):460-470. [2] LABAKI WW, ROSENBERG SR. Chronic Obstructive Pulmonary Disease[J]. Ann Intern Med, 2020, 173(3):ITC17-17ITC32. [3] HALPIN D, CELLI BR, CRINER GJ, et al.The GOLD Summit on chronic obstructive pulmonary disease in low-and middle-income countries[J]. Int J Tuberc Lung Dis, 2019, 23(11):1131-1141. [4] SANDELOWSKY H, WEINREICH UM, AARLI BB, et al.COPD-do the right thing[J]. BMC Fam Pract, 2021, 22(1):244. [5] COBELENS F, SURI RK, HELINSKI M, et al.Accelerating research and development of new vaccines against tuberculosis: a global roadmap[J]. Lancet Infect Dis, 2022, 22(4):e108-e120. [6] LEE CM, HEO J, HAN SS, et al.Inhaled corticosteroid related tuber-culosis in the real world among patients with asthma and COPD: a10-year nationwide population-based study[J]. J Allergy Clin Im-munol Pract, 2019, 7(4):1197-1206. [7] FAN H, WU F, LIU J, et al.Pulmonary tuberculosis as a risk factor for chronic obstructive pulmonary disease: a systematic review and meta-analysis[J]. Ann Transl Med, 2021, 9(5):390. [8] 李同霞,褚晏,林梅,等.6765例结核分枝杆菌培养阳性肺结核患者耐药及共病分析[J/CD].新发传染病电子杂志,2022, 7(4):12-15. [9] GUIEDEM E, IKOMEY GM, NKENFOU C, et al.Chronic obstructive pulmonary disease (COPD): neutrophils, macrophages and lymphocytes in patients with anterior tuberculosis compared to tobacco related COPD[J]. BMC Res Notes, 2018, 11(1):192. [10] KAMENAR K, HOSSEN S, GUPTE AN, et al.Previous tuberculosis disease as a risk factor for chronic obstructive pulmonary disease: a cross-sectional analysis of multicountry, population-based studies[J]. Thorax, 2022, 77(11):1088-1097. [11] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)[J]. 中华结核和呼吸杂志, 2013, 36(4):255-264. [12] 中华人民共和国国家卫生和计划生育委员会.肺结核诊断标准(WS 288—2017)[J/CD].新发传染病电子杂志,2018,3(1):59-61. [13] DE MARTINO M, LODI L, GALLI L, et al.Immune Response to Mycobacterium tuberculosis: A Narrative Review[J]. Front Pediatr, 2019, 7:350-357. [14] MI J, LIANG Y, LIANG J, et al.The Research Progress in Immunotherapy of Tuberculosis[J]. Front Cell Infect Microbiol, 2021, 11:1-17. [15] 涂军. TNF-α、IFN-γ及eGFR在老年肺结核患者中的表达意义及合并肺部感染患者的病原菌分布特点[J]. 中国医学创新, 2018, 15(23):99-103. [16] 杨红丽, 黎秋芬, 徐力超. 慢阻肺合并肺结核患者血清细胞因子水平变化与意义研究[J]. 实用心脑肺血管病杂志, 2019, 27(S1):117-119. [17] 周伊南, 朱惠莉. 慢性阻塞性肺疾病合并肺结核的研究进展[J].结核与肺部疾病杂志, 2022, 3(4):338-342. [18] 张信鸽, 刘新, 赵丹晖. IFN-γ、IL-6、sIL-2R在初治型肺结核患者血清中的变化意义研究[J]. 分子诊断与治疗杂志, 2020, 12(6):777-780. [19] 曾子航, 陈燕, 龙颖姣. 嗜酸性粒细胞型慢性阻塞性肺疾病的研究进展[J]. 结核与肺部疾病杂志, 2022, 3(1):50-54. [20] 聂文娟, 石文卉, 刘佩英, 等. 血清细胞因子TNF-α、IL-4、sIL-2R和IFN-γ对预测抗结核治疗效果的价值[J].中国防痨杂志, 2022, 44(10):1022-1027. [21] 徐慧, 赵登峰, 王淼, 等. 肺部感染对慢性阻塞性肺疾病患者呼吸功能状态与细胞因子表达的影响[J]. 中华医院感染学杂志, 2019, 29(7):1011-1014. [22] TANAKA T, NARAZAKI M, KISHIMOTO T.Interleukin (IL-6) Immunotherapy[J]. Cold Spring Harb Perspect Biol, 2018, 10(8):1-15. [23] 中华医学会变态反应学分会. 2型炎症性疾病机制及靶向治疗专家共识[J]. 中华医学杂志, 2022, 102(42):3349-3373. |